Exploring the Mechanism of Yiqi Qingre Ziyin Method in Regulating Neuropeptide Expression for the Treatment of Atrophic Rhinitis.

Tytuł:: Exploring the Mechanism of Yiqi Qingre Ziyin Method in Regulating Neuropeptide Expression for the Treatment of Atrophic Rhinitis.
Autorzy:: Lu L; Department of Otorhinolaryngology Head and Neck Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, China.
Kang X; Department of Otorhinolaryngology Head and Neck Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, China.
Yi B; Department of Otorhinolaryngology Head and Neck Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, China.
Jiang C; Department of Otorhinolaryngology Head and Neck Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, China.
Yan X; Department of Otorhinolaryngology Head and Neck Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, China.
Chen B; Department of Otorhinolaryngology Head and Neck Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, China.
Sun Y; Department of Otorhinolaryngology Head and Neck Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, China.
Shi F; Ear Institute Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases, China.
Luo Y; Department of Otorhinolaryngology Head and Neck Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, China.
Chen Y; Department of Sports Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Shi R; Department of Otorhinolaryngology Head and Neck Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, China.; Ear Institute Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Translational Medicine on Ear and Nose Diseases, China.
Źródło:: Disease markers [Dis Markers] 2022 Mar 08; Vol. 2022, pp. 4416637. Date of Electronic Publication: 2022 Mar 08 (Print Publication: 2022).
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: 2015- : New York, NY : Hindawi Pub. Corp.
Original Publication: Chichester ; New York : Wiley, c1983-
MeSH Terms:: Medicine, Chinese Traditional*
Molecular Docking Simulation*
Drugs, Chinese Herbal/*pharmacology
Neuropeptides/*metabolism
Rhinitis, Atrophic/*drug therapy
Computer Simulation ; Databases, Genetic ; Dipeptidyl Peptidase 4 ; Epithelial Cells/pathology ; Gene Ontology ; Humans ; Metaplasia/pathology ; Nasal Mucosa/immunology ; Nasal Mucosa/injuries
References:: Am J Otolaryngol. 1996 Mar-Apr;17(2):81-6. (PMID: 8820180)
Jibiinkoka. 1970 Oct;42(10):777-81. (PMID: 5529129)
Nucleic Acids Res. 2019 Jan 8;47(D1):D464-D474. (PMID: 30357411)
Scand J Immunol. 2007 Oct;66(4):451-7. (PMID: 17850590)
J Neuroimmunol. 2004 Apr;149(1-2):202-9. (PMID: 15020081)
Genome Res. 2003 Nov;13(11):2498-504. (PMID: 14597658)
Evid Based Complement Alternat Med. 2013;2013:591796. (PMID: 23476696)
Oxid Med Cell Longev. 2021 Dec 29;2021:8302831. (PMID: 35003520)
Nat Methods. 2017 Jan;14(1):71-73. (PMID: 27819658)
BMC Complement Altern Med. 2016 May 20;16:132. (PMID: 27207147)
J Comput Chem. 2005 Dec;26(16):1701-18. (PMID: 16211538)
Rhinology. 2010 Jun;48(2):206-10. (PMID: 20502762)
Handb Exp Pharmacol. 2018;247:131-145. (PMID: 28035534)
Scand J Immunol. 2001 Sep;54(3):249-64. (PMID: 11555388)
Bioinformatics. 2008 Jan 15;24(2):282-4. (PMID: 18006545)
J Allergy Clin Immunol. 2006 Nov;118(5):999-1016. (PMID: 17088122)
J Allergy Clin Immunol Pract. 2019 Nov - Dec;7(8):2850. (PMID: 31451401)
Ann Allergy Asthma Immunol. 2016 Jun;116(6):497-505. (PMID: 27156748)
Clin J Pain. 2010 Jan;26 Suppl 10:S10-5. (PMID: 20026960)
J Healthc Eng. 2021 Oct 25;2021:1536337. (PMID: 34733451)
Maturitas. 2019 Mar;121:41-47. (PMID: 30704564)
J Affect Disord. 2020 Jan 15;261:121-125. (PMID: 31610313)
J Ginseng Res. 2017 Oct;41(4):503-512. (PMID: 29021697)
Eur Arch Otorhinolaryngol. 2011 Jan;268(1):17-26. (PMID: 20878413)
J Neuroimmunol. 2006 Oct;179(1-2):163-72. (PMID: 16919783)
J Immunol. 2012 Jun 1;188(11):5438-47. (PMID: 22539793)
OMICS. 2012 May;16(5):284-7. (PMID: 22455463)
Am J Otolaryngol. 2020 May - Jun;41(3):102410. (PMID: 32098705)
J Ginseng Res. 2017 Jul;41(3):386-391. (PMID: 28701882)
J Ginseng Res. 2016 Oct;40(4):437-444. (PMID: 27746698)
Trends Pharmacol Sci. 2007 Jan;28(1):23-31. (PMID: 17150262)
Menopause. 2013 Apr;20(4):443-7. (PMID: 23211877)
Genome Biol. 2019 Jun 4;20(1):118. (PMID: 31164141)
BMC Res Notes. 2012 Jul 23;5:367. (PMID: 22824207)
J Ginseng Res. 2017 Apr;41(2):127-133. (PMID: 28413316)
Oxid Med Cell Longev. 2021 Aug 19;2021:5633514. (PMID: 34457116)
Biol Psychiatry. 2000 May 1;47(9):794-803. (PMID: 10812038)
Chem Biodivers. 2021 Jan;18(1):e2000810. (PMID: 33251769)
BMC Bioinformatics. 2019 Dec 27;20(Suppl 23):667. (PMID: 31881980)
Pain. 2003 Jan;101(1-2):199-208. (PMID: 12507715)
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613. (PMID: 30476243)
PeerJ. 2020 Sep 11;8:e9890. (PMID: 32974101)
J Tradit Chin Med. 2020 Aug;40(4):690-702. (PMID: 32744037)
Am J Hum Genet. 2002 Mar;70(3):787-92. (PMID: 11799475)
J Neuroimmunol. 2006 Dec;181(1-2):157-64. (PMID: 17081623)
Am J Rhinol. 2001 Nov-Dec;15(6):355-61. (PMID: 11777241)
J Chem Inf Model. 2015 Nov 23;55(11):2324-37. (PMID: 26479676)
Mini Rev Med Chem. 2009 Jan;9(1):31-59. (PMID: 19149659)
Cochrane Database Syst Rev. 2012 Feb 15;(2):CD008280. (PMID: 22336840)
Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368. (PMID: 27924014)
Oxid Med Cell Longev. 2021 Dec 26;2021:8060477. (PMID: 34987704)
J Cheminform. 2014 Apr 16;6:13. (PMID: 24735618)
Evid Based Complement Alternat Med. 2021 Oct 26;2021:6034147. (PMID: 34737779)
Substance Nomenclature:: 0 (Drugs, Chinese Herbal)
0 (Neuropeptides)
EC 3.4.14.5 (DPP4 protein, human)
EC 3.4.14.5 (Dipeptidyl Peptidase 4)
Entry Date(s):: Date Created: 20220318 Date Completed: 20220330 Latest Revision: 20220330
Update Code:: 20240105
PubMed Central ID:: PMC8923799
DOI:: 10.1155/2022/4416637
PMID:: 35299869
: Czasopismo naukowe

Pełny tekst

Atrophic rhinitis (AR) is a chronic disease that causes severe structural changes to the nasal mucosa leading to squamous epithelial metaplasia. However, treatment regarding AR remains a major challenge. We used network pharmacology and molecular docking methods to explore the potential mechanisms of the Yiqi Qingre Ziyin method to modulate neuropeptides in the treatment of AR. The active ingredients of the Yiqi Qingre Ziyin method and their targets of action were obtained from the Traditional Chinese Medicine Systematic Pharmacology Database Analysis Platform (TCMSP). Disease targets for AR were obtained from four databases: GeneCards, PharmGKB, DrugBank, and Online Mendelian Inheritance in Man (OMIM). A total of 59 active ingredients, 39 potential targets, and 76 relevant neuropeptides were obtained after deduplication. We constructed target interaction networks with the STRING database. Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed on the 14 potential target proteins. We used Cytoscape software to construct the "drug-active ingredient-potential target" and "ingredient-target-pathway" networks of the Yiqi Qingre Ziyin method for treating AR. Molecular docking results suggest that dipeptidyl peptidase 4 ( DPP4 ), opioid receptor gene d1 ( OPRD1 ), and opioid receptor m1 ( OPRM1 ) are key targets for the Yiqi Qingre Ziyin method. Therefore, this study proposed a potential mechanism for the treatment of AR by affecting the expression of neuropeptide-related genes (including DPP4 , OPRD1 , and OPRM1 ), which may potentially improve the immune microenvironment of the nasal mucosa.
Competing Interests: The authors declare there are no competing interests.
(Copyright © 2022 Lixing Lu et al.)

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja